statistical analysis software sas version 6.09 (SAS institute)
SAS institute is a verified supplier 
90
Structured Review
SAS institute
statistical analysis software sas version 6.09
Statistical Analysis Software Sas Version 6.09, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+software+version+6%2E09/sas+version+9+4/pm20546100-42-0-6
Average 90 stars, based on 1 article reviews
Statistical Analysis Software Sas Version 6.09, supplied by SAS institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/statistical+software+version+6%2E09/sas+version+9+4/pm20546100-42-0-6
Average 90 stars, based on 1 article reviews
statistical analysis software sas version 6.09 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Changes in serum concentrations of growth hormone, insulin, insulin-like growth factor and insulin-like growth factor-binding proteins 1 and 3 and urinary growth hormone excretion during the menstrual cycle. Article Snippet: The statistical analyses were carried out using Article Title: Patient complaints and malpractice risk. Article Snippet: All statistical analyses were performed using Article Title: Preinfarction blood pressure and smoking are determinants for a fatal outcome of myocardial infarction: a prospective analysis from the Finnmark Study. Article Snippet: All statistical modeling was performed with SAS Article Title: Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life. Article Snippet: Blood pressure and pulse rate analyses were conducted using analysis of variance with baseline value, treatment, and center included in the model. All demographic and efficacy analyses were conducted using SAS Article Title: An Assessment of Heart-Valve Abnormalities in Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or Placebo Article Snippet: A BSTRACT Background The appetite-suppressant drug fenfluramine, usually given in combination with phentermine, has been reported to be associated with cardiac valvular regurgitation.. Concern has been raised that the d -enantiomer of fenfluramine, dexfenfluramine, may also cause this problem.. We were able to study the question by modifying an ongoing trial comparing sustained-release dexfenfluramine with regular dexfenfluramine and placebo. |